Matthijs E. Dolman

Utrecht, UT 3584CS, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma.

Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma.

Journal: Journal of medicinal chemistry

Published: November 18, 2025

The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.

The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.

Journal: British journal of haematology

Published: August 14, 2025

High-throughput 3D engineered paediatric tumour models for precision medicine.

High-throughput 3D engineered paediatric tumour models for precision medicine.

Journal: Molecular systems biology

Published: August 13, 2025

Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.

Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.

Journal: Molecular cancer therapeutics

Published: July 01, 2025

Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.

Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.

Journal: Molecular cancer therapeutics

Published: July 01, 2025

A novel TRKB-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activation.

A novel TRKB-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activation.

Journal: NPJ precision oncology

Published: November 18, 2024

Author Correction: Functional precision medicine for pediatric cancers.

Author Correction: Functional precision medicine for pediatric cancers.

Journal: Nature medicine

Published: July 26, 2024

Functional precision medicine for pediatric cancers.

Functional precision medicine for pediatric cancers.

Journal: Nature medicine

Published: April 11, 2024

High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.

High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.

Journal: Cancer reports (Hoboken, N.J.)

Published: October 09, 2023

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.

Journal: Frontiers in oncology

Published: December 22, 2022

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.

Journal: Cancer research

Published: November 28, 2022

The potential of PARP as a therapeutic target across pediatric solid malignancies.

The potential of PARP as a therapeutic target across pediatric solid malignancies.

Journal: BMC cancer

Published: September 27, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026